Meanwhile, investors await key clinical data.
ApexOnco Front Page
Recent articles
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
The FDA throws out the company’s second attempt at an accelerated approval.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?